Clinical Trial Search

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 7; 2; 4; 5 Participants

Primary: Efficacy of Combination Sorafenib Plus Metronomic Cyclophosphamide in Advanced, Progressive NET, as Measured by the Objective Response Rate (ORR). — 1 Participants

Primary: Severity of Participants Reporting Study-related Adverse Events at Each Dose Level — 1; 1; 1; 1.25 units on a scale

Primary: Maximum Tolerated Dose (MTD) — 80 mg

Primary: Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluorescence (FAF) at Week 24 — 0.614; 1.121; 1.049; 0.911 mm^2 — p=0.0428

Primary: Percent Change In LDH Levels From Baseline To Day 253 And Day 281 — -72.85; -78.12; -84.96; -87.63 Percent Change — p=<0.0001

Primary: Percent of Patients With Complete Clearance of Lesions — 4; 4 Participants

Primary: Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/17/Duck/Potsdam/86/92 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated…

Primary: Change in QTcF (QT Corrected According to Fridericia's Formula) — 3.32; 1.76; 1.84; 1.32 ms (Milliseconds)

Primary: Individual Peak Booster Rate by ELISA (Percentage of Participants) — 100.0; 100.0 percentage of subjects

Primary: Part 1: Number of Participants Experiencing a Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants

Primary: Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.9 for Train-Of-Four (TOF) Stimulation — 66.90; 4.73; 3.43; 1.58…

Primary: Number of Subjects With Solicited Local and Systemic Adverse Reactions After Each Vaccination — 21; 25; 21; 21 Participants

Primary: Number of Participants With Treatment-related Adverse Events (AEs) — 1; 3; 2; 6 Participants